SCHEMBL4484974

SCHEMBL4484974

CN(C)CCCC(=O)N(C)c1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccc(CC(=O)O)cc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 7/20 0.36
KDM4E B2RXH2 2/20 0.35
MAPT P10636 1/20 0.35
CYP26B1 Q9NR63 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
PLK3 Q9H4B4 6/20 0.33
PDGFRB P09619 5/20 0.33
KDR P35968 5/20 0.33
KIT P10721 4/20 0.33
FGFR1 P11362 4/20 0.33
FLT3 P36888 4/20 0.33
CPT1A P50416 3/20 0.33
CPT1B Q92523 3/20 0.33
TERT O14746 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484977 1.00 PLK1 (0.36) PLK1KDM4EMAPTCYP26B1NR1H4
SCHEMBL4489146 0.98 PLK1 (0.35) PLK1KDM4EMAPTCYP26B1NR1H4
SCHEMBL4489144 0.98 PLK1 (0.35) PLK1KDM4EMAPTCYP26B1NR1H4
SCHEMBL4493805 0.96 KDM4E (0.36) PLK1KDM4EMAPTCYP26B1NR1H4
SCHEMBL4493803 0.96 KDM4E (0.36) PLK1KDM4EMAPTCYP26B1NR1H4
SCHEMBL223535 0.93 PLK1 (0.37) PLK1NR1H4PLK3PDGFRBKDR
SCHEMBL223536 0.93 PLK1 (0.37) PLK1NR1H4PLK3PDGFRBKDR
SCHEMBL225625 0.92 PLK1 (0.36) PLK1NR1H4PLK3PDGFRBKDR
SCHEMBL4501991 0.92 PLK1 (0.39) PLK1KDM4EMAPTNR1H4PLK3
SCHEMBL4501993 0.92 PLK1 (0.39) PLK1KDM4EMAPTNR1H4PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR PLK1 86/4885KDM4E 1648/4885MAPT 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.